Key Takeaways & Executive Findings
- •• SMG-1 is overexpressed in HNSCC tissues compared to normal counterparts, suggesting a potential oncogenic role. • SMG-1 knockdown does not affect HNSCC cell proliferation or tumor growth in vitro and in vivo, indicating a non-essential role in tumor progression. • SMG-1 expression status does not correlate with overall survival in radiotherapy-naïve HNSCC patients, but SMG-1 knockdown enhances radiosensitivity in vitro. • SMG-1 may serve as a prognostic indicator for radiotherapy response in HNSCC, warranting further clinical validation.
Abstract
Head and neck squamous cell carcinoma (HNSCC) is a common malignancy where radiotherapy is a primary treatment. The prognostic value of SMG-1, a PIKK family member involved in DNA damage response, remains controversial. This study investigated SMG-1 expression in HNSCC and its impact on tumor growth, prognosis, and radiosensitivity. Using bioinformatics analysis, we found elevated SMG-1 mRNA in HNSCC tissues. Knockdown of SMG-1 in SCC-090 cells did not affect proliferation in vitro or tumor growth in xenografts. In a cohort of 36 radiotherapy-naïve HNSCC patients, SMG-1 protein expression did not correlate with overall survival. However, SMG-1 knockdown enhanced radiosensitivity in vitro, suggesting SMG-1 as a potential prognostic indicator for radiotherapy response. These findings highlight the need for further validation in larger clinical cohorts.
1. Introduction
Head and neck cancer (HNC) is one of the most common types of malignant cancer worldwide, originating in the oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, and sinonasal tract. The most common type is head and neck squamous cell carcinoma (HNSCC). Radiotherapy is a primary treatment for HNSCC, and identifying prognostic indicators for radiotherapy response is crucial for clinical management.
SMG-1, a member of the phosphoinositide 3-kinase (PI3K)-related kinase (PIKK) family, was initially identified as a critical component of nonsense-mediated mRNA decay (NMD). It has also been implicated in DNA damage response and cell cycle regulation. SMG-1's role in cancer is controversial, with both tumor-suppressive and oncogenic functions reported across different cancer types. In HNSCC, its exact function remains unclear, necessitating further investigation with reliable evidence from animal models and clinical data.
Loading authentic research manuscript (Pages 1–5)...
Xiaofeng Wang, Yuxia Zou, Ren-Bo Ding, Xueying Lyu, Yuanfeng Fu, Xuejun Zhou, Zhihua Sun, Jiaolin Bao (2026). SMG-1 serves as a prognostic indicator for the radiotherapy response in head and neck squamous cell carcinoma xenografts and patients. Acta Biochimica et Biophysica Sinica. https://doi.org/10.3724/abbs.2024180
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the role of SMG-1 in head and neck squamous cell carcinoma (HNSCC)?
SMG-1 is overexpressed in HNSCC tissues, but its knockdown does not affect tumor growth or patient prognosis. However, SMG-1 knockdown enhances radiosensitivity, suggesting it may serve as a prognostic indicator for radiotherapy response.
How was SMG-1 expression assessed in this study?
SMG-1 mRNA levels were analyzed using bioinformatics across 31 cancer types, and protein expression was assessed via immunohistochemistry in a cohort of 36 HNSCC patients.
Does SMG-1 affect HNSCC cell proliferation?
No, SMG-1 knockdown did not affect HNSCC cell proliferation in vitro or tumor growth in a mouse xenograft model.
What is the clinical significance of SMG-1 in HNSCC?
SMG-1 expression does not correlate with overall survival in radiotherapy-naïve patients, but its knockdown increases radiosensitivity, indicating it could be a biomarker for predicting radiotherapy response.
What are the future directions based on this study?
Further validation in larger clinical cohorts and mechanistic studies are needed to confirm SMG-1 as a prognostic indicator and to explore its potential as a therapeutic target to enhance radiotherapy efficacy.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.